Nanhua Historical Income Statement

000504 Stock

10.27 0.02 0.20%

Historical analysis of Nanhua Bio income statement accounts such as Selling General Administrative of 43 M, Total Revenue of 117.7 M or Cost Of Revenue of 69.4 M can show how well Nanhua Bio Medicine performed in making a profits. Evaluating Nanhua Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Nanhua Bio's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Nanhua Bio Medicine latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Nanhua Bio Medicine is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Nanhua Bio Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Nanhua Income Statement Analysis

Nanhua Bio Medicine Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Nanhua Bio shareholders. The income statement also shows Nanhua investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Nanhua Bio Income Statement Chart

At present, Nanhua Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Cost Of Revenue is expected to grow to about 69.4 M, whereas Selling General Administrative is forecasted to decline to about 43 M.

Selling General Administrative Total Revenue Cost Of Revenue Other Operating Expenses Total Operating Expenses Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Nanhua Bio Medicine generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Cost Of Revenue

Cost of Revenue is found on Nanhua Bio Medicine income statement and represents the costs associated with goods and services Nanhua Bio provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Nanhua Bio Medicine. It is also known as Nanhua Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Nanhua Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Nanhua Bio Medicine current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Nanhua Bio Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	45.7M	70.5M	43.7M	69.4M
Total Revenue	156.6M	200.3M	136.8M	117.7M

Cost Of Revenue Total Revenue

Nanhua Bio income statement Correlations

	Selling General Administrative	Total Revenue	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Operating Income	Other Operating Expenses	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Gross Profit	Net Income From Continuing Ops	Ebit	Research Development	Total Operating Expenses	Ebitda	Reconciled Depreciation
Selling General Administrative		0.9	0.56	-0.62	-0.55	0.25	0.08	-0.41	0.14	0.1	-0.81	0.74	0.95	-0.67	-0.77	0.69	0.95	0.61	0.88
Total Revenue	0.9		0.8	-0.53	-0.47	0.27	0.19	-0.35	0.31	0.13	-0.65	0.59	0.91	-0.56	-0.66	0.66	0.92	0.71	0.77
Cost Of Revenue	0.56	0.8		-0.36	-0.36	0.27	0.03	-0.32	0.3	0.12	-0.31	0.35	0.55	-0.35	-0.41	0.31	0.61	0.52	0.37
Income Before Tax	-0.62	-0.53	-0.36		0.97	-0.31	0.28	0.71	-0.22	0.2	0.82	-0.79	-0.58	0.99	0.9	-0.68	-0.63	-0.13	-0.72
Net Income	-0.55	-0.47	-0.36	0.97		-0.27	0.41	0.63	-0.33	0.22	0.75	-0.66	-0.48	0.96	0.86	-0.61	-0.54	-0.06	-0.6
Income Tax Expense	0.25	0.27	0.27	-0.31	-0.27		0.02	-0.55	-0.35	0.42	-0.07	0.51	0.31	-0.31	-0.1	0.09	0.31	0.0	0.28
Operating Income	0.08	0.19	0.03	0.28	0.41	0.02		0.19	-0.28	0.53	0.21	0.05	0.28	0.25	0.28	-0.16	0.22	0.24	0.03
Other Operating Expenses	-0.41	-0.35	-0.32	0.71	0.63	-0.55	0.19		0.11	-0.11	0.47	-0.69	-0.41	0.72	0.6	-0.42	-0.51	-0.06	-0.5
Minority Interest	0.14	0.31	0.3	-0.22	-0.33	-0.35	-0.28	0.11		-0.48	-0.28	-0.22	0.17	-0.25	-0.42	0.45	0.23	0.45	0.11
Tax Provision	0.1	0.13	0.12	0.2	0.22	0.42	0.53	-0.11	-0.48		0.24	0.08	0.15	0.15	0.33	-0.34	0.11	-0.23	-0.09
Net Interest Income	-0.81	-0.65	-0.31	0.82	0.75	-0.07	0.21	0.47	-0.28	0.24		-0.72	-0.74	0.84	0.93	-0.84	-0.75	-0.36	-0.9
Interest Income	0.74	0.59	0.35	-0.79	-0.66	0.51	0.05	-0.69	-0.22	0.08	-0.72		0.72	-0.8	-0.7	0.52	0.72	0.21	0.82
Gross Profit	0.95	0.91	0.55	-0.58	-0.48	0.31	0.28	-0.41	0.17	0.15	-0.74	0.72		-0.63	-0.7	0.75	0.98	0.71	0.9
Net Income From Continuing Ops	-0.67	-0.56	-0.35	0.99	0.96	-0.31	0.25	0.72	-0.25	0.15	0.84	-0.8	-0.63		0.92	-0.69	-0.68	-0.17	-0.75
Ebit	-0.77	-0.66	-0.41	0.9	0.86	-0.1	0.28	0.6	-0.42	0.33	0.93	-0.7	-0.7	0.92		-0.81	-0.77	-0.42	-0.81
Research Development	0.69	0.66	0.31	-0.68	-0.61	0.09	-0.16	-0.42	0.45	-0.34	-0.84	0.52	0.75	-0.69	-0.81		0.74	0.6	0.87
Total Operating Expenses	0.95	0.92	0.61	-0.63	-0.54	0.31	0.22	-0.51	0.23	0.11	-0.75	0.72	0.98	-0.68	-0.77	0.74		0.72	0.88
Ebitda	0.61	0.71	0.52	-0.13	-0.06	0.0	0.24	-0.06	0.45	-0.23	-0.36	0.21	0.71	-0.17	-0.42	0.6	0.72		0.55
Reconciled Depreciation	0.88	0.77	0.37	-0.72	-0.6	0.28	0.03	-0.5	0.11	-0.09	-0.9	0.82	0.9	-0.75	-0.81	0.87	0.88	0.55

Click cells to compare fundamentals

Nanhua Bio Account Relationship Matchups

Nanhua Bio income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	8.9M	4.0M	14.1M	11.9M	10.2M	10.7M
Selling General Administrative	48.6M	48.0M	72.5M	76.2M	53.2M	43.0M
Total Revenue	134.2M	175.6M	156.6M	200.3M	136.8M	117.7M
Cost Of Revenue	49.7M	78.1M	45.7M	70.5M	43.7M	69.4M
Income Before Tax	17.4M	19.0M	(30.2M)	(21.6M)	(44.7M)	(42.5M)
Net Income Applicable To Common Shares	18.8M	8.2M	(19.1M)	(12.7M)	(11.4M)	(10.9M)
Net Income	18.8M	8.2M	(19.1M)	(12.7M)	(28.2M)	(26.8M)
Income Tax Expense	(819.5K)	4.3M	2.9M	8.2M	9.4M	9.9M
Operating Income	(13.8M)	24.4M	4.0M	12.2M	(9.1M)	(8.6M)
Other Operating Expenses	992.3K	1.2M	1.1M	394.1K	354.7K	337.0K
Minority Interest	96.0M	107.9M	14.0M	17.1M	18.6M	17.7M
Tax Provision	(819.5K)	4.3M	2.9M	8.2M	2.1M	3.2M
Net Interest Income	(10.5M)	(3.3M)	(14.0M)	(11.6M)	(9.1M)	(9.6M)
Interest Income	179.4K	138.9K	2.5M	1.8M	2.3M	2.5M
Gross Profit	84.5M	97.5M	110.9M	129.8M	93.1M	85.0M
Net Income From Continuing Ops	18.3M	14.6M	(33.1M)	(29.8M)	(46.8M)	(44.4M)
Ebit	(12.1M)	20.5M	(21.7M)	(19.7M)	(17.7M)	(16.9M)
Research Development	15.5M	5.0M	8.5M	10.0M	12.6M	9.7M
Total Operating Expenses	139.3M	151.1M	152.6M	188.1M	145.8M	144.8M
Ebitda	32.0M	26.3M	(9.2M)	(3.5M)	(4.0M)	(3.8M)
Reconciled Depreciation	5.7M	3.4M	6.9M	6.2M	6.3M	5.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Other Information on Investing in Nanhua Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Nanhua Historical Income Statement

About Nanhua Income Statement Analysis

Nanhua Bio Income Statement Chart

Total Revenue

Cost Of Revenue

Other Operating Expenses

Total Operating Expenses

Nanhua Bio income statement Correlations

Nanhua Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Nanhua Bio income statement Accounts

Also Currently Popular

Other Information on Investing in Nanhua Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income From Continuing Ops	+ 0.99	Income Before Tax
Total Operating Expenses	+ 0.98	Gross Profit
Net Income	+ 0.97	Income Before Tax
Net Income From Continuing Ops	+ 0.96	Net Income
Gross Profit	+ 0.95	Selling General Administrative
Total Operating Expenses	+ 0.95	Selling General Administrative

Reconciled Depreciation	- 0.9	Net Interest Income
Research Development	- 0.84	Net Interest Income
Reconciled Depreciation	- 0.81	Ebit
Research Development	- 0.81	Ebit
Net Interest Income	- 0.81	Selling General Administrative
Net Income From Continuing Ops	- 0.8	Interest Income